Ceftaroline fosamil: A novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue SUPPL. 4, 2010, Pages

  Biek, Donald ^a   Critchley, Ian A ^a   Riccobene, Todd A ^b   Thye, Dirk A ^a  

^a Cerexa Inc   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Complicated skin and skin structure infections; MRSA activity; Novel cephalosporins

Indexed keywords

AZTREONAM; CEFTAROLINE FOSAMIL; CEFTRIAXONE; LINEZOLID; OXACILLIN; PENICILLIN BINDING PROTEIN 2A; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL SKIN DISEASE; BINDING AFFINITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IC 50; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PNEUMOCOCCAL INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS PNEUMONIAE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICROBIAL SENSITIVITY TESTS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME;

EID: 78649452602     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq251     Document Type: Article

References (32)

1. Darville T, Yamauchi T. The cephalosporin antibiotics. Pediatr Rev 1994; 15: 54-62.
2. Kalman D, Barriere SL. Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins. Tex Heart Inst J 1990; 17: 203-15.
3. Williams JD. Classification of cephalosporins. Drugs 1987; 34 Suppl 2: 15-22.
4. Lim D, Strynadka NC. Structural basis for the β-lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat Struct Biol 2002; 9: 870-6.
5. Long TE. Recent progress toward the clinical development of new anti-MRSA antibiotics. IDrugs 2003; 6: 351-9.
6. Pan A, Lorenzotti S, Zoncada A. Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. Recent Pat Antiinfect Drug Discov 2008; 3: 10-33.
7. Guignard B, Entenza JM, Moreillon P. β-Lactams against methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 2005; 5: 479-89.
8. Ishikawa T, Nakayama Y, Tomimoto M et al. Studies on anti-MRSA parenteral cephalosporins, IV: a novel water-soluble N-phosphono type prodrug for parental administration. J Antibiot (Tokyo) 2001; 54: 364-74.
9. Page MG. Anti-MRSA β-lactams in development. Curr Opin Pharmacol 2006; 6: 480-5.
10. Ishikawa T, Matsunaga N, Tawada H et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003; 11: 2427-37.
11. Eckburg P, Friedland D, Lee J et al. FOCUS 1 and 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline (CPT) vs ceftriaxone (CRO) in community-acquired pneumonia (CAP). In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Poster L1-345a. American Society for Microbiology, Washington, DC, USA.
12. Corey GR, Wilcox MH, Talbot GH et al. on behalf of the CANVAS 1 investigators. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: iv41-51.
13. Wilcox MH, Corey GR, Talbot GH et al. on behalf of the CANVAS 2 investigators. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: iv53-65.
14. Kosowska-Schick K, McGhee P, Appelbaum P. Affinity of ceftaroline (CPT) and other β-lactams for penicillin-binding proteins (PBPs) from Staphylococcus aureus and Streptococcus pneumoniae. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract C1-1350. American Society for Microbiology, Washington, DC, USA.
15. Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother 2010; 65: 713-6.
16. Tipper DJ, Strominger JL. Biosynthesis of the peptidoglycan of bacterial cell walls, XII: inhibition of cross-linking by penicillins and cephalosporins: studies in Staphylococcus aureus in vivo. J Biol Chem 1968; 243: 3169-79.
17. Fuda C, Suvorov M, Vakulenko SB et al. The basis for resistance to β-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus. J Biol Chem 2004; 279: 40802-6.
18. Ge Y, Biek D, Talbot GH et al. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008; 52: 3398-407.
19. Jacqueline C, Caillon J, Le Mabecque V et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007; 51: 3397-400.
20. Kanafani ZA, Corey GR. Ceftaroline: a cephalosporin with expanded Gram-positive activity. Future Microbiol 2009; 4: 25-33.
21. Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother 2009; 53: 4712-7.
22. Zhanel GG, Sniezek G, Schweizer F et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs 2009; 69: 809-31.
23. Villegas-Estrada A, Lee M, Hesek D et al. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA β-lactam antibiotics. J Am Chem Soc 2008; 130: 9212-3.
24. Sader HS, Fritsche TR, Kaniga K et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005; 49: 3501-12.
25. Sader HS, Moet G, Jones RN. In vitro activity of ceftaroline tested against recent clinical isolates from the United States. In: Abstracts of the Forty-seventh Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, 2009. Abstract 894. Infectious Diseases Society of America, Arlington, VA, USA.
26. Jones RN, Fritsche TR, Sader HS. Ceftaroline activity tested against organisms causing skin and skin structure infections (SSSI) isolated in U.S. and European medical centers in 2008. In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008. Abstract C1-160. American Society for Microbiology, Washington, DC, USA.
27. Ge Y, Redman R, Floren L et al. The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous (IV) infusions. In: Abstracts of the Forty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2006. Abstract A-1937. American Society for Microbiology, Washington, DC, USA.
28. Riccobene T, Fang E, Thye D. A single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaroline (CPT) administered by intramuscular (IM) injection to healthy subjects. In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008. Abstract A-1888. American Society for Microbiology, Washington, DC, USA.
29. Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 2006; 50: 1376-83.
30. Ge Y, Liao S, Talbot GH. Population pharmacokinetics (PK) analysis of ceftaroline (CPT) in volunteers and patients with complicated skin and skin structure infection (CSSI). In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract A-34. American Society for Microbiology, Washington, DC, USA.
31. Ge Y, Liao S, Thye D et al. Ceftaroline (CPT) dose adjustment recommendations for subjects with mild or moderate renal impairment (RI). In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract A-35. American Society for Microbiology, Washington, DC, USA.
32. Corey GR, Wilcox M, Talbot GH et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51: 641-50.